TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29265039

Group type: EXPERIMENTAL
Intervention: Pathway care (PC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 38
Study: 27082507

Group type: EXPERIMENTAL
Intervention: Systems engineering intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Systems engineering intervention in Kenya
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (Control) in Kenya
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Systems engineering intervention in Mozambique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (Control) in Mozambique
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 24955669

Group type: EXPERIMENTAL
Intervention: 2‐session adolescent only (BI‐A)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 2‐session adolescent and additional parent session (BI‐AP)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Assessment only control condition (CON)
Number of subjects: 284
Study: 22999399

Group type: EXPERIMENTAL
Intervention: 0.25mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 0.5mg.kg(‐1) of S(+)‐ ketamine diluted in 20mL of saline solution 0.9% (Group B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 20mL of intra‐articular saline 0.9% (Group C)
Number of subjects: 56
Study: 19321098

Group type: EXPERIMENTAL
Intervention: Elastic Taping (ET)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Inelastic Taping (IT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No Taping (Control)
Number of subjects: 27
Study: 17552381

Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (ASV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spontaneous sleep (control)
Number of subjects: 10
Study: 15110021

Group type: EXPERIMENTAL
Intervention: Dexmedotomidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11411623

Group type: EXPERIMENTAL
Intervention: Compression sleeve worn for 5 days following eccentric exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no compression sleeve)
Number of subjects: 20
Study: 9343285

Group type: EXPERIMENTAL
Intervention: Calcium Supplement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: British Mothers
Number of subjects: 60
Study: 7872895

Group type: EXPERIMENTAL
Intervention: Cisplatin followed by 120-hr continuous 5-FU infusion (Group A)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cisplatin administered 72 hr after the initiation of continuous 5-FU infusion (Group B)
Number of subjects: 130
Study: 3146539

Group type: EXPERIMENTAL
Intervention: Enprostil 70 mcg/d
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29461989

Group type: EXPERIMENTAL
Intervention: CHARMS intervention (sexual counseling during cardiac rehabilitation)
Number of subjects: 29
Study: 28245843

Group type: EXPERIMENTAL
Intervention: PRIME intervention involving recruitment strategies discussion and software provision for patient eligibility extraction.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control state (no intervention) during the initial phase before the intervention was delivered.
Number of subjects: 72
Study: 26680431

Group type: COMPARATOR
Intervention: Standard label
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Text warning label
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Text and image warning label
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Plain bottle with text and image warning
Number of subjects: 92
Study: 23945170

Group type: EXPERIMENTAL
Intervention: Adipose tissue content of marine n-3 PUFA
Number of subjects: 3440

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Number of subjects: 3440

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Number of subjects: 3440

Group type: EXPERIMENTAL
Intervention: Docosapentaenoic acid
Number of subjects: 3440
Study: 21414185

Group type: EXPERIMENTAL
Intervention: Living arrangements for people with dementia (LAD-study)
Number of subjects: 0
Study: 19040645

Group type: EXPERIMENTAL
Intervention: Insulin glulisine at breakfast
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Insulin glulisine at main mealtime
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Patients with HbA(1c) >7.0% at baseline
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia
Number of subjects: 393
Study: 16600443

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (104.7, 105.2, or 106.1 ffu)
Number of subjects: 2464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464
Study: 15023613

Group type: COMPARATOR
Intervention: DASH type diet (OD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low sodium, high potassium diet (LNAHIK)
Number of subjects: 94

Group type: COMPARATOR
Intervention: High dairy diet (HID)
Number of subjects: 94
Study: 15129595

Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication (5 micrograms/kg 1 hr before anesthesia)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 24
Study: 10423465

Group type: EXPERIMENTAL
Intervention: Oral therapy with ciprofloxacin (750 mg twice daily) plus amoxicillin‐clavulanate (625 mg three times daily)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Intravenous therapy with ceftriaxone plus amikacin
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for oral therapy
Number of subjects: 353

Group type: COMPARATOR
Intervention: Intention-to-treat analysis for intravenous therapy
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Duration of fever
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Time to a change in regimen
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Reasons for change in regimen
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Duration of therapy
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 353
Study: 8523657

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (1 mg.kg‐1 administered 15 minutes before operation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (intravenous NaCl 0.9%)
Number of subjects: 26
Study: 2266262

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study: 109198

Group type: EXPERIMENTAL
Intervention: Abdominopelvic radiation
Number of subjects: 231

Group type: COMPARATOR
Intervention: Pelvic radiation alone or followed by chlorambucil
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: None (stage IA patients with well-differentiated tumors)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Poorly differentiated tumors
Number of subjects: 231
Study: 30817709

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Health Education (HE) control
Number of subjects: 24
Study: 28376188

Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation (RNI)
Number of subjects: 1664

Group type: COMPARATOR
Intervention: Non-regional nodal irradiation (non-RNI)
Number of subjects: 1664
Study: 26349479

Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (LIF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conservative standard treatment (CST)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (LIF) and Conservative standard treatment (CST)
Number of subjects: 72
Study: 22947235

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.125% and 0.25% bupivacaine
Number of subjects: 30
Study: 21884542

Group type: EXPERIMENTAL
Intervention: Strongly identified young adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expecting to identify with future aged in-group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Membership in future in-group being highly salient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants' written descriptions of old age and valence manipulation
Number of subjects: 0
Study: 19335503

Group type: EXPERIMENTAL
Intervention: At-home preparation group (experimental group)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care group (control group)
Number of subjects: 158
Study: 17269982

Group type: EXPERIMENTAL
Intervention: 10% silver nitrate solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Black ink (placebo)
Number of subjects: 60
Study: 15516638

Group type: COMPARATOR
Intervention: Standard treatment (14 days of ferrous sulfate and an antimalarial)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Extended treatment (three months of ferrous sulfate and three antimalarial treatments)
Number of subjects: 209
Study: 11699685

Group type: EXPERIMENTAL
Intervention: Receiving welfare
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Leaving welfare by child's third birthday
Number of subjects: 833
Study: 9446377

Group type: EXPERIMENTAL
Intervention: Colon interposition with anastomosis to gastric fundus
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Isoperistaltic grafts
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Antiperistaltic grafts
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 113
Study: 8182625

Group type: EXPERIMENTAL
Intervention: Etodolac coadministered with MTX (10 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: MTX (10 mg) without etodolac
Number of subjects: 19
Study: 30196174

Group type: EXPERIMENTAL
Intervention: Group A: KWs affixed to surgical towels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Group B: Screws with metal extensors
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Group C: Screws with plastic extensors (K2M)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Group D: Screws without extensors or tulips (Nuvasive)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Precept Modular (Nuvasive)
Number of subjects: 16
Study: 27650977

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 736

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 736
Study: 25638698

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CTI ablation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (PVI)
Number of subjects: 60
Study: 23622565

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics + oral steroids (Group 2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intravenous antibiotics (Group 1)
Number of subjects: 21
Study: 21183919

Group type: EXPERIMENTAL
Intervention: Adaptol (32 patients)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Pantoham (30 patients)
Number of subjects: 189
Study: 18467719

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg daily
Number of subjects: 416

Group type: COMPARATOR
Intervention: Hormone therapy (HT)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg daily (in patients with EGFR-overexpressed tumors)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Hormone therapy (HT) (in patients with EGFR-overexpressed tumors)
Number of subjects: 416
Study: 16331117

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 135
Study: 12583871

Group type: EXPERIMENTAL
Intervention: buspirone (5HT1A receptor agonist)
Number of subjects: 40
Study: 10885420

Group type: EXPERIMENTAL
Intervention: Supervised training on a treadmill, 4 days/week (group S; n=21)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self-monitored walking 3 or 4 km in 1 h, 4 days/week (group SM; n=20)
Number of subjects: 35
Study: 8772550

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg orally at -270 min and 250 mg orally at -60 min)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally at -60 min) with Acipimox
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms iv at 0 min) with Acipimox
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-6 (100 micrograms iv at 0 min) with Acipimox
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (administered at similar intervals as Acipimox)
Number of subjects: 31
Study: 1602106

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% (Voltaren)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin 1% (Indocid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 4091874

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg capsules, daily dosage limited to 400 mg for 3 weeks)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Naloxone (1.6 mg i.m.)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Saline (i.m.)
Number of subjects: 153
Study: 29571962

Group type: EXPERIMENTAL
Intervention: Heparin-free TPE
Number of subjects: 164

Group type: COMPARATOR
Intervention: Unfractionated heparin TPE
Number of subjects: 164
Study: 26295176

Group type: EXPERIMENTAL
Intervention: Individual nutritional counseling for seven sessions (baseline, weeks 2, 4, 8, 12, 18, and 24)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard verbal diet information at baseline and nutritional counseling only at week 24
Number of subjects: 72
Study: 24772412

Group type: COMPARATOR
Intervention: 3 mL 0.5% levobupivacaine solution at room temperature (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 mL 0.5% levobupivacaine solution at 37 °C (Group II)
Number of subjects: 0
Study: 22248499

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte drink (CHO-E; Lucozade Sport)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Flavor-matched placebo-electrolyte (PL)
Number of subjects: 22
Study: 20363153

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (US)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Computed tomographic (CT) angiography
Number of subjects: 83
Study: 19010143

Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) (n = 20)
Number of subjects: 40
Study: 15707927

Group type: EXPERIMENTAL
Intervention: Facial expression processing with gaze direction influence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverted faces in expression judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gaze judgments influenced by expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity of expression processing to gaze direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judgments of gaze direction
Number of subjects: 0
Study: 12441015

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine, enalapril, hydrochlorothiazide, or both to control systolic blood pressure to <150 mmHg
Number of subjects: 2418

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 2418

Group type: EXPERIMENTAL
Intervention: Lacidipine and lercanidipine
Number of subjects: 2418
Study: 9934943

Group type: EXPERIMENTAL
Intervention: TPQ Novelty Seeking subscale score
Number of subjects: 170
Study: 7587747

Group type: EXPERIMENTAL
Intervention: VCS-microsphere method
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: VCS-microsphere method with CD3 gating
Number of subjects: 76
Study: 2178396

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily until complete ulcer healing (Group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ranitidine 150 mg until complete relief of pain (Group B)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily (Group A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ranitidine treatment (both groups)
Number of subjects: 81
Study: 550419

Group type: EXPERIMENTAL
Intervention: Metrizamide (Amipaque; Winthrop)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dimer‐X
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Number of subjects: 150
Study: 31174502

Group type: EXPERIMENTAL
Intervention: School-based skills-training program to improve skills to deal with performance anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-based skills-training program to improve social skills
Number of subjects: 0
Study: 29936455

Group type: EXPERIMENTAL
Intervention: Oligomeric proanthocyanidin (OPC) 150 mg/day for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 27344831

Group type: EXPERIMENTAL
Intervention: Point application treatment using herbal plaster on acupoints Dingchuan (EX-B1), Feishu (BL 13), Gaohuang (BL 43), and Danzhong (CV 17) for 2 to 4 hours on the first day of each of the three periods of the hot season.
Number of subjects: 135
Study: 25260636

Group type: COMPARATOR
Intervention: Control (lactated Ringer's)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nNOS inhibitor (5 mm N-propyl-l-arginine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eNOS inhibitor (10 mm N(5)-(1-iminoethyl)-l-ornithine dihydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-selective NOS inhibitor (20 mm Nω-nitro-l-arginine methyl ester hydrochloride)
Number of subjects: 0
Study: 22418272

Group type: EXPERIMENTAL
Intervention: Education + access
Number of subjects: 96

Group type: COMPARATOR
Intervention: Access-only
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 19883910

Group type: EXPERIMENTAL
Intervention: Mini‐incision surgery (MIS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard incision (STD)
Number of subjects: 56
Study: 17629164

Group type: EXPERIMENTAL
Intervention: 50 microg vaginal misoprostol
Number of subjects: 147

Group type: COMPARATOR
Intervention: 25 microg vaginal misoprostol
Number of subjects: 147
Study: 15894947

Group type: EXPERIMENTAL
Intervention: Training (T) - 45 minutes cycling at intensity corresponding to anaerobic threshold, 4 to 5 times per week for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 54
Study: 12540357

Group type: EXPERIMENTAL
Intervention: Stroke unit care
Number of subjects: 216

Group type: COMPARATOR
Intervention: General medical wards care
Number of subjects: 216
Study: 10589633

Group type: EXPERIMENTAL
Intervention: Forearm IVRA (0.4 mL/kg, max 25 mL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional IVRA (0.6 mL/kg, max 45 mL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional IVRA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Forearm IVRA
Number of subjects: 14
Study: 8727014

Group type: EXPERIMENTAL
Intervention: Shoulder muscle fatigue
Number of subjects: 80

Group type: COMPARATOR
Intervention: Active and passive repositioning tests
Number of subjects: 80

Group type: COMPARATOR
Intervention: Arm dominance
Number of subjects: 80
Study: 1927586

Group type: EXPERIMENTAL
Intervention: 60 mg of pseudoephedrine four times a day for 3 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo capsules four times a day for 3 days
Number of subjects: 29
Study: 6349925

Group type: COMPARATOR
Intervention: Monophasic oral contraceptive Neovletta (30 micrograms ethinyl oestradiol + 150 micrograms levonorgestrel)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Three-phasic oral contraceptive Trionetta (30/40/30 micrograms ethinyl oestradiol + 50/75/125 micrograms levonorgestrel)
Number of subjects: 835
Study: 31674252

Group type: EXPERIMENTAL
Intervention: Monolateral fixator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Circular frame
Number of subjects: 30
Study: 27210034

Group type: EXPERIMENTAL
Intervention: Single implants placed in healed ridges
Number of subjects: 96

Group type: COMPARATOR
Intervention: Single implants placed in extraction sockets
Number of subjects: 96
Study: 26524414

Group type: EXPERIMENTAL
Intervention: Lidcombe Program (LP)
Number of subjects: 199

Group type: COMPARATOR
Intervention: RESTART-DCM
Number of subjects: 199
Study: 23422190

Group type: EXPERIMENTAL
Intervention: GnRHa cotreatment during chemotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no GnRHa)
Number of subjects: 16
Study: 21157444

Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day for 8 weeks)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 19136094

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 60
Study: 17143197

Group type: EXPERIMENTAL
Intervention: Resperate device-guided breathing exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (listened to music, no therapeutic device)
Number of subjects: 30
Study: 15383479

Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH) or IV unfractionated heparin (UFH) for short-term treatment of DVT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulants while awaiting diagnostic tests for patients with high clinical suspicion of DVT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial treatment with LMWH or UFH for at least 5 days for acute DVT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term treatment with VKA for 3 months for first episode of DVT secondary to a transient risk factor.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment with VKA for at least 6 to 12 months for first episode of idiopathic DVT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose of VKA adjusted to maintain a target INR of 2.5 (range 2.0 to 3.0).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of elastic compression stocking for prevention of postthrombotic syndrome.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute treatment with SC LMWH or IV UFH for objectively confirmed nonmassive PE.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendation against systemic thrombolytic therapy for most patients with PE.
Number of subjects: 0